Compare Carvana Co (CVNA) vs Eli Lilly And Co (LLY) Price & Performance

Carvana (CVNA) trades at $65.02, down 1.23% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong revenue growth to $20.32 billion in 2025 and a net income of $1.41 billion, though it missed Q3 2025 EPS estimates. Recent corporate actions include stock splits, and cash flow from operations remains positive at $1.04 billion in 2025. Analyst consensus is a Buy with a $93.62 price target, indicating significant upside potential from current levels.

The outlook for CVNA is mixed; robust revenue growth and improving profitability support bullish sentiment, but high valuation ratios (P/E of 37.65) and technical bearishness pose risks. Investors should weigh the company's scaling efficiency and market share gains against debt levels and competitive pressures in the e-commerce auto sector. The stock's proximity to support at $64 suggests near-term volatility, but analyst targets imply confidence in long-term value.

Eli Lilly (LLY) trades at $1,185.08, down slightly (-0.29%) on the day, with a strong bullish technical signal from moving averages. The company demonstrates exceptional fundamental strength, with revenue surging to $65.18B in 2025 and a net income margin of 34.99%. Recent earnings have consistently beaten expectations, and analyst sentiment is overwhelmingly positive, with a consensus price target of $1,360.

The outlook for LLY remains robust, driven by its dominant position in the high-growth weight loss and Alzheimer's drug markets. Key opportunities include continued revenue expansion and pipeline advancements. Primary risks involve intensifying competition, particularly from Novo Nordisk's obesity pill, and the stock's premium valuation multiples, which demand sustained high growth to justify.